Plasma lipocalin-2 levels in pregnant women with pre-eclampsia, and their relation with severity of disease

References

• Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006;8:1–20.
   PubMedGoogle Scholar
• Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004;175:189–202.
   PubMed Web of Science ®Google Scholar
• van Beck E, Peeters LL. Pathogenesis of preeclampsia: a comprehensive model. Obstet Gynecol Surv 1998;53:233–239.
   PubMedGoogle Scholar
• Fasshauer M, Seeger J, Waldeyer T, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R. Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens 2008;21:582–586.
   PubMed Web of Science ®Google Scholar
• Zavalza-Gomez AB, Anaya-Prado R, Rincon-Sanchez AR, Mora-Martinez JM. Adipokines and insulin resistance during pregnancy. Diabetes Res Clin Pract 2008; 80:8–15.
   PubMed Web of Science ®Google Scholar
• Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 2008;69:878–884.
   PubMed Web of Science ®Google Scholar
• Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006;58:81–88.
   PubMedGoogle Scholar
• Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917–921.
   PubMed Web of Science ®Google Scholar
• Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005;123:1293–1305.
   PubMed Web of Science ®Google Scholar
• Triebel S, Bläser J, Reinke H, Tschesche H. A 25 kDa α 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386–388.
   PubMed Web of Science ®Google Scholar
• Liu Q, Nilsen-Hamilton M. Identification of a new acute phase protein. J Biol Chem 1995;270:22565–22570.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, et al Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34–41.
   PubMed Web of Science ®Google Scholar
• Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, Houstis NE, Kahn BB, Rosen ED. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533–2540.
   PubMed Web of Science ®Google Scholar
• Aigner F, Maier HT, Schwelberger HG, Wallnofer EA, Amberger A, Obrist P, Berger T, Mak TW, Maglione M, Margreiter R, et al Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am J Transplant 2007;7:779–788.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008;22:1416–1426.
   PubMedGoogle Scholar
• ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American college of obstetricians and gynecologists. Int J Gynaecol Obstet 2002;77:67–75.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Edelstam G, Wbeer CL, Kral C, Gustafsson SA, Venge P. New reference values for routine blood samples and human neutrophilic lipocalin during third trimester pregnancy. Scand J Clin Lab Invest 2001;61:583–592.
   PubMed Web of Science ®Google Scholar
• D'Anna R, Baviera G, Giordano D, Russo S, Dugo N, Santamaria A, Corrado F. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn 2009;29:1066–1068. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• D'Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand 2008;87:1370–1373.
   PubMed Web of Science ®Google Scholar
• Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004;70:223–232.
   PubMed Web of Science ®Google Scholar
• Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens 2004;17:154–160.
   PubMed Web of Science ®Google Scholar
• Kauma S, Takacs P, Scordalakes C, Walsh S, Green K, Peng T. Increased endothelial monocyte chemoattractant protein-1 and interleukin-8 in preeclampsia. Obstet Gynecol 2002;100:706–714.
   PubMed Web of Science ®Google Scholar
• Stewart FM, Freeman DJ, Ramsay JE, Greer IA, Caslake M, Ferrell WR. Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers. J Clin Endocrinol Metab 2007;92:969–975.
   PubMed Web of Science ®Google Scholar
• Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006;11:309–316.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499–506.
   PubMed Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Gil MJ, Cienfuegos JA, Salvador J, Frühbeck G. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med 2009;87:803–813.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 2008;158:525–531.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53.
   PubMed Web of Science ®Google Scholar
• Tan BK, Adya R, Shan X, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by insulin. Diabetes Care 2009;32:129–131.
   PubMed Web of Science ®Google Scholar
• Elneihoum AM, Falke P, Hedblad B, Lindga¨rde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79–84.
   PubMed Web of Science ®Google Scholar
• Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008;158:203–207.
   PubMed Web of Science ®Google Scholar